Fusion Pharmaceuticals rises on radioisotope supply deal with Niowave

Fusion Pharmaceuticals

10/06/2022 15:06

** Shares of biotech firm  FUSN.O  up 4.3% at $3.86 
    ** Announces collaboration and supply deal with Niowave - 
supplier of medical and industrial radioisotopes - for
development, production and supply of actinium-225
    ** Ac-225, decay product of thorium-229, is used for
targeted treatment of certain types of prostate, brain and
neuroendocrine cancers
    ** To invest up to $5 mln in Niowave for strengthening
technology to boost actinium-225 production
    ** Niowave to give FUSN guaranteed access to
pre-determined pct of capacity of resulting actinium-225
    **Stock down ~7% YTD

 (Reporting by Richard Rohan Francis in Bengaluru)
 ((RichardRohan.Francis@thomsonreuters.com;))